We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 
Introduction
The 2016 European Society of Cardiology heart failure (HF) guidelines recognized the gap in evidence for patients with HF and ejection fraction (EF) in the middle range of 40-49% (HFmrEF) between HF with reduced (HFrEF; <40%) and preserved (HFpEF; ≥50%) EF.
1,2 Emerging data from registry and cohort settings are inconsistent regarding whether clinical characteristics in HFmrEF may be more similar to in HFrEF or HFpEF or intermediate. 3 -10 Little is known regarding cause-specific outcomes, which may be especially important for testing existing or developing novel interventions for HFmrEF. Finally, although EF in HFmrEF is not normal, there is currently no evidence-based therapy in this EF category.
The Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Programme studied patients with symptomatic HF across the spectrum of EF and represents an opportunity to assess the characteristics, outcomes and efficacy of angiotensin receptor blockade across the entire EF spectrum. In CHARM, increasing EF was associated with better outcomes until approximately 45%, without further improvement at higher EFs.
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In CHARM-Preserved, which enrolled patients with left ventricular EF >40%, candesartan did not significantly reduce cardiovascular death or HF hospitalization [unadjusted hazard ratio 0.89, 95% confidence interval (CI) 0.77-1.03, P = 0.118; covariate adjusted 0.86, IC 95% 0.74-1.0, P = 0.051). 12 However, it was effective in HFrEF, and in CHARM-Overall, there was no heterogeneity with respect to EF (P = 0.33). The potential benefit in the HFmrEF range has not been specifically reported. 13 We used data from the CHARM Programme to assess the relationship between EF and patient characteristics and outcomes, and tested the hypothesis that candesartan improves outcomes in HFmrEF.
Methods

Patients
The rationale and design 14 and main outcomes 15 of the CHARM Programme have been described previously. Briefly, 7599 patients with symptomatic HF were randomized to candesartan vs. placebo in three separate trials, CHARM-Added [EF ≤40% treated with an angiotensin-converting enzyme (ACE) inhibitor, n = 2548], CHARM-Alternative (EF ≤40% intolerant to an ACE inhibitor, n = 2028), and CHARM-Preserved (EF >40%, 19% treated with an ACE inhibitor, n = 3023). For the present analysis, the 7598 patients with available integer digit EF were divided into HFrEF (EF <40%), HFmrEF (EF 40-49%), and HFpEF (EF ≥50%).
The primary outcome was time to cardiovascular death or first HF hospitalization. Additional pre-specified outcomes included time to first HF hospitalization, all-cause hospitalization, cardiovascular death, and all-cause death, and rate of recurrent HF hospitalizations.
Statistical methods
Baseline characteristics across the three EF groups were summarized using means and standard deviations or medians (interquartile ranges) for continuous data, or percentages for categorical data, respectively. Trend tests were performed across EF groups using linear regression for continuous data and 2 tests for categorical data.
The association between EF and outcomes was assessed in the overall population (irrespective of treatment assignment) with EF as three categories and as a continuous independent variable, and outcomes as the dependent variable. For associations between EF and outcomes, incidence rates per 100 patient-years were calculated for each outcome in each EF group. The associations between EF groups and all time to first outcomes were assessed with univariable and multivariable Cox regressions and between EF groups and rates of recurrent HF hospitalizations using univariable and multivariable negative binomial regression models which take both time to and number of events into account. The multivariable Cox models violated the proportional hazards assumption; therefore stratified models using age, treatment assignment and body mass index deciles were entered as stratification factors, after which the proportional hazards assumption was no longer violated. The adjusted associations between EF as a continuous variable and outcomes were plotted using multivariable restricted cubic splines models with five knots, using Poisson regression models to estimate incidence rates for time to first event outcomes and using negative binomial regression for the recurrent HF hospitalizations outcome.
The effect of candesartan vs. placebo was assessed in the three EF categories and in the overall population with EF as a continuous variable. Incidence rate ratios were calculated for candesartan vs. placebo for each outcome within each EF group. The interactions between treatment and EF category were also examined using Cox models. Within EF categories, the effect of candesartan on time to the primary composite outcome was assessed with Kaplan-Meier analysis, for the primary and four additional time to first event outcomes from the original CHARM Programme with univariable Cox regressions, and for the recurrent outcome using univariable negative binomial regression. For EF as a continuous variable, the effect of candesartan was modelled using univariable restricted cubic splines with three knots, using Poisson regression for time to first outcomes and negative binomial regressions for the recurrent outcome.
Patients lost to follow-up (n = 10) were censored alive at last follow-up. Statistical analyses were performed in Stata v. 14 (Stata Corp., College Station, TX, USA). The CHARM Programme was approved by local ethics boards. All patients provided written informed consent.
Results
Ejection fraction and baseline characteristics
Of 7599 patients enrolled in CHARM, EF was available in 7598 patients with 4323 (57%) patients falling into the HFrEF range, 1322 patients (17%) falling into the HFmrEF range, and 1953 patients (26%) falling into the HFpEF range. HFmrEF resembled HFrEF regarding most characteristics including age, systolic blood pressure, percent women, previous myocardial infarction, and atrial fibrillation ( Table 1) . HFmrEF was intermediate between HFrEF and HFpEF with regard to history of hypertension, distribution of New York Heart Association class, and body mass index (P for trend over EF categories <0.001 for all). Some characteristics, such as diabetes mellitus (P for trend = 0.71), were similarly prevalent in all three EF categories. Data are expressed as numbers (%), mean ± standard deviation, or median (interquartile range). ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, ejection fraction; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure. * P for trend over EF categories. Table 2 . The range shaded blue is the heart failure with mid-range ejection fraction category. CV, cardiovascular; HF, heart failure; py, patient-years.
Ejection fraction and outcomes (irrespective of treatment assignment)
all-cause death were similar in patients with HFmrEF and those with HFpEF, and considerably lower than in those with HFrEF. The incidence of all-cause hospitalization was somewhat lower in HFmrEF than in HFrEF and HFpEF. Figure 1 shows adjusted incidence rates for each outcome according to continuous EF. For the primary, cardiovascular death and all-cause death outcomes, the risk decreased steeply with increasing EF until EF around 50%, and the risk was flat thereafter. For first HF hospitalization, first all-cause hospitalization and recurrent HF hospitalization, the risk decreased with increasing EF until EF around 40%. The P-value overall and the P-value for non-linearity for EF and all outcomes were <0.001. Figure 2 shows Kaplan-Meier curves with time to the primary outcome for each of the three EF groups. Candesartan showed a beneficial effect compared to placebo in HFrEF and HFmrEF but not in HFpEF. In HFpEF, candesartan did not significantly reduce any outcome, but for recurrent HF hospitalizations, the hazard ratio was 0.78 (95% CI 0.59-1.03; P = 0.08). There was no significant interaction between EF group and treatment in the association between treatment and outcomes, except for the all-cause death outcome. placebo for the primary composite outcome: time to cardiovascular death or first heart failure hospitalization for the three ejection fraction categories. Large graphs show y-axis up to 1.0; inserted graphs show y-axis up to 0.4. HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio.
Ejection fraction and candesartan treatment effect
Discussion
In this large and long-term clinical trial programme of patients with HF including EF across the entire spectrum, we found that (i) HFmrEF resembled HFrEF with respect to many baseline characteristics, including age, gender and history of myocardial infarction; (ii) HFmrEF resembled HFpEF with respect to lower risk of HF and cardiovascular events; and (iii) candesartan reduced the composite of cardiovascular death and HF hospitalization, as well as first and recurrent HF hospitalizations, in HFrEF and HFmrEF but not in HFpEF, although there was no statistical interaction between EF category and candesartan treatment effect. We recognize, along with others, that EF is not an optimal classifier in HF, 1,15 that cut-offs are arbitrary, and that other tools to identify disease-specific phenotypes may emerge as more important than EF. However, EF remains the most commonly used classifier. Clinical trials, drug labels, treatment guidelines, and reimbursement schemes are based on EF cut-offs. 2 4, 17 Thus, whether a separate phenotype or part of a continuum, HFmrEF is common, and data regarding patient characteristics and outcomes and response to therapy are clinically relevant and relevant for trial design. The boundary for 'normal EF' remains controversial but the EchoNoRMAL study suggested a lower limit of 49-57%, depending on age, sex and ethnicity. 18 According to the American Society of Echocardiography and European Association of Cardiovascular Imaging, the normal EF and normal range (±2 standard deviations) is 62% (52-72%) in men and 64% (54-74%) in women.
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In HF, the EF distribution was bimodal in the OPTIMIZE-HF registry 20 and in Olmsted County 21 but unimodal and normally distributed in CHARM. 11 Regardless of distribution, most studies have consistently shown that patients with EF in the 40-50% range constitute up to 20% of the HF population. 4, 11, 17, 20, 21 Thus HFmrEF is not infrequently encountered in clinical settings. Data are expressed as number (%) of participants with events, and incidence rate per 100 py, HR (95% confidence interval).
CV, cardiovascular; EF, ejection fraction; HF, heart failure; HR, hazard ratio; IRR, incidence rate ratio; py, patient-years.
Figure 3
Effect of candesartan on all outcomes by ejection fraction as a continuous variable. Unadjusted incidence rate ratios and 95%
confidence intervals for the candesartan treatment effect for the six outcomes according to ejection fraction as a continuous variable. The range shaded blue is the heart failure with mid-range ejection fraction category. CV, cardiovascular; HF, heart failure.
Ejection fraction and baseline characteristics
HFmrEF is often termed 'intermediate' but our findings challenge this. Some baseline characteristics in HFmrEF were intermediate between HFrEF and HFpEF. However, HFmrEF distinctly resembled HFrEF in several important aspects, including age, sex and ischaemic heart disease and history of myocardial infarction, consistent with other emerging analyses. 8 With improved and earlier treatment for myocardial infarction, the importance of the HFmrEF category may also be increasing over time. While diabetes was equally common in all EF categories it may contribute differently to HF, by contributing to ischaemic heart disease and myocardial infarction in lower EF and together with obesity and other co-morbidities potentially to microvascular inflammation, fibrosis and diastolic dysfunction in higher EF.
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Ejection fraction and outcomes
Prior studies have described the association of EF with outcomes in HF: the risk for cardiovascular outcomes declined as EF increased up to 45% in the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) 24 
CHARM.
11 In the present analysis, crude cardiovascular event rates were similar in HFmrEF and HFpEF and much lower than in HFrEF; and analogously, the adjusted hazard ratios demonstrated lower risk in HFmrEF and HFpEF compared to HFrEF. However, regarding the importance of incremental increases in EF, the HFmrEF group was similar to HFrEF in that an increasing EF was associated with improving prognosis (up-sloping curves in spline analyses in Figure 1 up to EF ∼50%), whereas within the HFpEF group, changes in EF were not related to prognosis (flat curves). This is also consistent with the risk of non-cardiovascular events, particularly all-cause hospitalization, increasing with the highest EF, where co-morbidity and frailty may be drivers of both deconditioning and HF symptoms (which may be difficult to interpret and in trials may have led to inclusion of patients without HF), as well as non-cardiovascular outcomes.
HFpEF trials in CHARM, extensive trial data that have been positive in HFrEF and neutral in HFpEF, and new designation of HFmrEF, this post-hoc analysis of pre-specified EF strata was considered justified, novel, and important.
We found that in HFrEF and HFmrEF candesartan appeared to significantly reduce the primary composite of time to cardiovascular death or HF hospitalization and time to HF hospitalization, as well as the novel outcome recurrent HF hospitalization, with hazard ratios and incidence rate ratios similar in HFrEF and HFmrEF and clinically meaningful approximately 20% reductions in time to first cardiovascular events and more than 30% reductions in recurrent HF hospitalization. However, since event rates were lower in HFmrEF than in HFrEF, the absolute risk reductions will also be lower in HFmrEF than in HFrEF. Spline analyses with EF as a continuous variable confirmed these findings, with candesartan efficacy constant at lower EFs and generally beginning to decline as EF moved above 50%. In the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial (HFrEF defined as EF ≤40%), the beneficial effect of sacubitril/valsartan was similar regardless of EF. 25 This is consistent with our observations of a similar treatment effect of candesartan regardless of EF up to ∼50% (flat sections of curves in Figure 3 ). In the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, spironolactone was not effective in HFpEF defined as EF ≥45%, but there was a suggestion of potential efficacy with lower EF and declining efficacy with increasing EF 26 ; this is consistent with our observations of declining effect of candesartan with increasing EF in and above the HFmrEF range (upsloping sections of curves in Figure 3 ). The present findings now demonstrate HF treatment efficacy in the HFmrEF range. These findings raise the possibility that the arbitrary EF 35% or 40% cut-offs used in many previous trials may have excluded patients who would potentially have derived benefit from the many interventions proven to be effective in HFrEF.
Limitations
The sample size of 7958 provided convincing efficacy results for the lower EF spectrum and narrow confidence intervals throughout a broad EF spectrum. However, at the extremes of EF statistical power was limited. Multiple outcomes and testing as well as the post-hoc nature of this analysis increase the risk that some of the findings may have occurred by chance. EF may change over time and there is inherent variability in EF measurements but this is likely in both directions without systematic bias, and with this large sample size, the consequences of measurement error are reduced. There is an even-digit bias in assigning EF and unconventional, uneven EF categories may reduce the risk of systematic miss-classification. 26 However, with existing trial cut-off and our focus specifically on the newly designated HFmrEF category, we conducted our analyses using even digit cut-offs. HFpEF with regard to risk of cardiovascular and HF outcomes, which was lower than in HFrEF. Importantly, candesartan improved outcomes in the HFmrEF range. This finding should be interpreted with caution because this was a post-hoc analysis and there was no statistical interaction between EF category and candesartan treatment. Thus whether patients in the HFmrEF range might benefit from therapies shown to be effective in HFrEF must be considered a hypothesis only.
Conclusion
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